199 related articles for article (PubMed ID: 6415314)
41. [Evaluation of clinical trials on adjuvant chemotherapy for curatively resected gastric cancer].
Kitamura M; Arai K; Iwasaki Y
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1221-9. PubMed ID: 9279340
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
[TBL] [Abstract][Full Text] [Related]
43. [Adjuvant chemotherapy for advanced gastric cancer].
Furukawa H; Hiratsuka M; Iwanaga T; Imaoka S; Ishikawa O; Kabuto T; Sasaki Y; Kameyama M; Ohigashi H; Nakamori S; Nakano H; Yasuda T
Nihon Geka Gakkai Zasshi; 1996 Apr; 97(4):312-6. PubMed ID: 8692150
[TBL] [Abstract][Full Text] [Related]
44. The treatment of advanced gastric cancer.
Wils J
Semin Oncol; 1996 Jun; 23(3):397-406. PubMed ID: 8658224
[TBL] [Abstract][Full Text] [Related]
45. Overview of adjuvant therapy for resected gastric cancer: differences in Japan and the United States.
Ohtsu A; Sasako M
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S101-4. PubMed ID: 16399444
[TBL] [Abstract][Full Text] [Related]
46. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
[TBL] [Abstract][Full Text] [Related]
47. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi J; Lim H; Nam DK; Kim HS; Cho DY; Yi JW; Kim HC; Cho YK; Kim MW; Joo HJ; Lee KB; Kim KB
Br J Cancer; 2001 Jan; 84(2):186-92. PubMed ID: 11161374
[TBL] [Abstract][Full Text] [Related]
48. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.
Petrioli R; Sabatino M; Roviello F; Marrelli D; Nastri G; Marsili S; Correale P; Pozzessere D; Messinese S; De Martino A; Tani F; Marzocca G; Lorenzi M; Civitelli S; Tanzini G; Pinto E; Francini G
Hepatogastroenterology; 2005; 52(65):1626-30. PubMed ID: 16201130
[TBL] [Abstract][Full Text] [Related]
49. Post-operative chemotherapy in non-curative gastrectomy for advanced gastric cancer.
Hanazaki K; Mochizuki Y; Machida T; Yokoyama S; Sodeyama H; Sode Y; Wakabayashi M; Kawamura N; Miyazaki T
Hepatogastroenterology; 1999; 46(26):1238-43. PubMed ID: 10370699
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy of gastric cancer.
Schein PS
Acta Chir Scand Suppl; 1988; 541():13-5. PubMed ID: 2455406
[No Abstract] [Full Text] [Related]
51. [Prospective randomized controlled study of bestatin in gastric cancer surgery].
Yoshinaka K; Tanaka T; Takagami S; Saeki T; Nishiyama M; Toge T; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1988 Mar; 15(3):493-8. PubMed ID: 3126708
[TBL] [Abstract][Full Text] [Related]
52. [Postoperative radio-chemotherapy in locally advanced gastric cancer].
Garrido M; Bustos M; Orellana E; Madrid J; Galindo H; Sánchez C; Pimentel F; Guzmán S; Ibáñez L; Butte JM; Alvarez M; Besa P
Rev Med Chil; 2008 Jul; 136(7):844-50. PubMed ID: 18949159
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of intensive adjuvant chemotherapy in gastric cancer using life expectancy compared with log-rank test as a measure of survival benefit.
Nishikawa T; Maetani S
Ann Surg Oncol; 2007 Feb; 14(2):348-54. PubMed ID: 17091331
[TBL] [Abstract][Full Text] [Related]
54. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial.
Lygidakis NJ; Sgourakis G; Aphinives P
Hepatogastroenterology; 1999; 46(27):2035-8. PubMed ID: 10430393
[TBL] [Abstract][Full Text] [Related]
55. [Chemotherapy of stomach cancer].
Gropp C; Havemann K
Z Gastroenterol; 1982 Dec; 20(12):703-9. PubMed ID: 6819730
[TBL] [Abstract][Full Text] [Related]
56. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up.
Neri B; Cini G; Andreoli F; Boffi B; Francesconi D; Mazzanti R; Medi F; Mercatelli A; Romano S; Siliani L; Tarquini R; Moretti R
Br J Cancer; 2001 Apr; 84(7):878-80. PubMed ID: 11286464
[TBL] [Abstract][Full Text] [Related]
57. [Significance of neoadjuvant chemotherapy for gastric cancer].
Fujii M; Kochi M; Mochizuki F
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2028-32. PubMed ID: 11103233
[TBL] [Abstract][Full Text] [Related]
58. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer.
Grau JJ; Martín M; Fuster J; Pera M; García-Valdecasas JC; Bombí JA; Bordas JM; Alcobendas F; Grande L; Estapé J
J Surg Oncol; 2003 Apr; 82(4):234-40. PubMed ID: 12672007
[TBL] [Abstract][Full Text] [Related]
59. [MQF-OK therapy in advanced terminal stomach cancer--with special reference to a comparison with MFC therapy].
Sakata Y; Yoshida Y; Komatsu Y; Sugawara K; Nishimura S; Kikuchi K
Gan To Kagaku Ryoho; 1982 Jan; 9(1):109-15. PubMed ID: 6820875
[TBL] [Abstract][Full Text] [Related]
60. [Postoperative adjuvant immunochemotherapy with bestatin for stomach cancer. Randomized controlled trial: first report].
Yoshinaka K; Nakano A; Toge T; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1458-64. PubMed ID: 3925887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
